Palisade bio announces positive data from two ex vivo translational studies of pali-2108 for the treatment of ulcerative colitis

Targeted, better-tolerated oral pde4 inhibitors are an unmet need in inflammatory bowel disease (ibd) pali-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing pde4 inhibitors data presented at the american college of gastroenterology's (acg) 2024 annual scientific meeting carlsbad, ca, oct. 31, 2024 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (“palisade,” “palisade bio” or the “company”), a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases has announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of pali-2108 in stool samples and whole blood. this orally administered, colon-specific phosphodiesterase-4 (pde4) inhibitor prodrug is in development for patients with ulcerative colitis (uc).
PALI Ratings Summary
PALI Quant Ranking